Establishment Labs Holdings (ESTA) Shares Just Moved, So What Is Driving Attention Now?
Establishment Labs Holdings (ESTA) drew investor attention after reporting second quarter 2026 results with higher sales and a smaller net loss than a year earlier, along with slightly raised full year revenue guidance.
See our latest analysis for Establishment Labs Holdings.
At a share price of $79.47, Establishment Labs Holdings has a 1 day share price return of 5.13% and a 90 day share price return of 20.85%, while the 1 year total shareholder return of 107.39% points to strong momentum despite a 30 day share price return that is down 12.30%.
If positive earnings surprises in medical technology have your attention, this could be a good moment to scan the wider healthcare AI space using the 44 healthcare AI stocks.
After a sharp move and a guidance upgrade, Establishment Labs Holdings now trades at a clear discount to analyst targets, while its own valuation model implies a premium. Is the market rightly cautious or mispricing the stock?
Most Popular Narrative: 16.6% Undervalued
At $79.47, the most widely followed narrative puts Establishment Labs Holdings' fair value at $95.33, which frames the recent rally in a different light.
Improving operational leverage via stable operating expenses, moderation in cash use, and anticipated EBITDA and cash flow breakeven milestones points toward expanding net margins and earnings scalability as revenues continue to rise. Secular growth tailwinds, such as a rising global middle class and broadening social acceptance of aesthetic and reconstructive procedures, are expected to drive higher procedure volumes globally, underpinning multi-year revenue, margin, and earnings growth for Establishment Labs Holdings.
Analysts are not just plugging in generic growth guesses. They are incorporating rapid revenue expansion, a swing to profits, and a rich future earnings multiple that is usually reserved for market leaders. This raises the question of which assumptions have the biggest impact on that $95.33 figure and how much perfection is already embedded in the story.
Result: Fair Value of $95.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points for Establishment Labs Holdings, including high SG&A and R&D spending and reliance on the Motiva implant portfolio, that could challenge this upbeat narrative.
Find out about the key risks to this Establishment Labs Holdings narrative.
Another View on Establishment Labs Holdings Valuation
Analysts frame Establishment Labs Holdings as 16.6% undervalued at $79.47 versus a fair value of $95.33. Yet on sales multiples the picture flips. The stock trades on a P/S of 9.6x, compared with 2.9x for the US Medical Equipment industry and 2.6x for peers, and above a fair ratio of 5.8x, which points to a richer valuation that could compress if sentiment cools.
For a closer look at how this price lines up against fundamentals, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
With sentiment clearly leaning toward optimism around Establishment Labs Holdings, this is a good time to review the underlying data yourself and decide how convincing the case really is. To see what the optimism is built on, take a closer look at the 2 key rewards.
Ready To Find More Investment Ideas Beyond Establishment Labs Holdings?
If Establishment Labs Holdings has sharpened your focus, now is the time to widen your search and line up a few more stocks on your watchlist.
- Spot potential upside early by scanning screener containing 18 high quality undiscovered gems that combine solid fundamentals with relatively low market attention.
- Build a core watchlist anchored in resilience through 83 resilient stocks with low risk scores that prioritise stronger balance sheets and steadier risk profiles.
- Target quality at a price that looks more appealing using the 50 high quality undervalued stocks and see which stocks currently screen as attractively priced.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com